Skip to content

Clinical trials

Hyperlipoproteinemia Type II trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hyperlipoproteinemia Type II Country / region: United States Clear all

69 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20036
20052
20063
20073
20082
20093
20101
20113
20122
20141
20151
20167
20173
20181
20193
20202
20212
20226
20236
20246
20252
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed45
Recruiting11
Terminated7
Enrolling by invitation3
Not yet recruiting1
Unknown status1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Kastle Therapeutics, LLC6
Novartis Pharmaceuticals5
Amgen4
Merck Sharp & Dohme LLC4
Pfizer4
University of Pennsylvania4
Geisinger Clinic3
NewAmsterdam Pharma3
REGENXBIO Inc.3
AstraZeneca2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hyperlipoproteinemia Type II69
Hypercholesterolemia26
Homozygous Familial Hypercholesterolemia18
Hyperlipidemias16
Atherosclerosis11
Dyslipidemias11
Genetic Diseases, Inborn9
Metabolic Diseases9
Cardiovascular Diseases6
Lipid Metabolism Disorders6

Trials

Showing 1 to 25 of 69. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.